Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives

医学 彭布罗利珠单抗 转移性尿路上皮癌 阿维鲁单抗 杜瓦卢马布 化疗 肿瘤科 免疫疗法 内科学 靶向治疗 阿替唑单抗 顺铂 临床试验 膀胱癌 癌症 尿路上皮癌
作者
Roberto Iacovelli,Carlo María Cicala,Chiara Ciccarese,Emilio Sacco,Marco Racioppi,Pier Francesco Bassi,Giampaolo Tortora
出处
期刊:Rivista Urologia [SAGE Publishing]
卷期号:90 (1): 3-10 被引量:12
标识
DOI:10.1177/03915603221139907
摘要

Metastatic urothelial carcinoma (mUC) is a lethal disease for which platinum-based chemotherapy represents the standard of care; however, long-term survival is achieved only in a minority of patients. Recently, along with important advances in the comprehension of the biology of this disease, the treatment paradigm of mUC has undergone a rapid expansion with the approval of several immune-checkpoint inhibitors (ICIs) and targeted agents in both first- and second-line settings. Cisplatin-based chemotherapy remains the backbone of first-therapy for mUC; nevertheless, for those patients who do not progress after the full course of first-line chemotherapy, maintenance treatment with the anti-PD-L1 avelumab showed to prolong overall survival compared observation alone. Moreover, the disappointing results of chemotherapy in pre-treated patients have led to the investigation and the subsequent approval of the anti-PD-1 pembrolizumab, which showed an unprecedented survival benefit when compared to second-line chemotherapy. Recently, target therapy with the antibody-drug conjugate (ADC) enfortumab vedotin, directed against Nectin-4, showed outstanding results in patients treated with both chemotherapy and immunotherapy. The FGFR inhibitor erdafitinib and sacituzumab govitecan, an ADC targeting Trop-2, demonstrated encouraging activity in phase II studies and are currently under investigation in randomized phase III trials. ICIs and targeted therapies also demonstrated promising results as first-line treatment of cisplatin-ineligible patients; randomized trials of ICIs alone or in combination with targeted agents are ongoing and may broaden the therapeutic armamentarium for this category of patients. In this review, we describe the current state of art for the treatment of mUC; in addition, we present the latest evidences from the most recent literature and congress presentations. Finally, we illustrate the key ongoing clinical trials, focusing on ICIs and target therapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
lingming完成签到,获得积分10
1秒前
1秒前
江江发布了新的文献求助20
1秒前
啦啦完成签到,获得积分20
1秒前
忧心的曼凝的应助被oioi采纳,获得10
1秒前
唐荣完成签到,获得积分10
1秒前
雪白的芒果完成签到,获得积分10
2秒前
谢尔顿完成签到,获得积分10
2秒前
高贵黄豆发布了新的文献求助10
2秒前
悦耳易完成签到,获得积分10
2秒前
李健的应助被叶闭月采纳,获得10
2秒前
萨阿呢完成签到,获得积分10
3秒前
3秒前
3秒前
超级无敌发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
3秒前
李老头发布了新的文献求助10
3秒前
4秒前
从容寻芹发布了新的文献求助10
4秒前
238167123发布了新的文献求助10
4秒前
4秒前
4秒前
5秒前
5秒前
5秒前
小二郎的应助被科研通管家采纳,获得10
5秒前
luyue9406的应助被科研通管家采纳,获得10
6秒前
打打的应助被科研通管家采纳,获得10
6秒前
SciGPT的应助被科研通管家采纳,获得10
6秒前
爆米花的应助被风笛采纳,获得10
6秒前
6秒前
华仔的应助被qianzhihe采纳,获得10
6秒前
ttt完成签到,获得积分10
6秒前
爆米花的应助被科研通管家采纳,获得10
6秒前
酷波er的应助被科研通管家采纳,获得10
6秒前
CodeCraft的应助被科研通管家采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181155
求助须知:如何正确求助?哪些是违规求助? 9571140
关于积分的说明 21816740
捐赠科研通 7777528
什么是DOI,文献DOI怎么找? 3433436
关于科研通互助平台的介绍 2557664
邀请新用户注册赠送积分活动 2479482